Giuliamarta Bottoni, Ph.D.’s Post

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/Ikc130sBx5G #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/749V30sBx4s #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/1fjU30sBxf2 #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/ThWY30sByl0 #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/Buya30sBz8u #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/V2B930sBz8K #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/2TYV30sBxlr #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/snh830sBAnP #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/qMYm30sBH4X #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)